onr:"swepub:oai:lup.lub.lu.se:4193784d-f6f0-485c-bbb9-08311c04530d"
Search: onr:"swepub:oai:lup.lub.lu.se:4193784d-f6f0-485c-bbb9-08311c04530d" > A phase 3 randomize...
- 1 of 1
- Previous record
- Next record
- To hitlist
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
- Carducci, Michael A. (author)
- Saad, Fred (author)
-
- Abrahamsson, Per-Anders (author)
- Lund University,Lunds universitet,Urologi, Malmö (Abrahamsson),Forskargrupper vid Lunds universitet,Urological research, Malmö,Lund University Research Groups
- show more...
- Dearnaley, David R. (author)
- Schulman, Claude C. (author)
- North, Scott A. (author)
- Sleep, Darryl J. (author)
- Isaacson, Jeffrey D. (author)
- Nelson, Joel B. (author)
- show less...
- (creator_code:org_t)
- 2007
- 2007
- English.
- In: Cancer. - : Wiley. - 1097-0142 .- 0008-543X. ; 110:9, s. 1959-1966
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- BACKGROUND. The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin-A receptor antagonist, in patients with metastatic hormone- refractory prostate cancer (HRPC). METHODS. This multinational, double-blind, placebo-controlled trial enrolled 809 men with metastatic HRPC. Patients were randomized 1:1 to receive either atrasentan 10 mg per day or placebo. The primary endpoint was time to disease progression (TTP), which was determined according to radiographic and clinical measures. Analyses of overall survival and changes in biomarkers also were performed. RESULTS. Atrasentan did not reduce the risk of disease progression relative to placebo (hazards ratio, 0.89; 95% confidence interval, 0.76-1.04; P =.136). Most patients progressed radiographically at the first 12-week bone scan without concomitant clinical progression. In exploratory analyses, increases from baseline to final bone alkaline phosphatase (BAP) and prostate-specific antigen (PSA) levels were significantly lower with atrasentan treatment (P <.05 for each). The median time to BAP progression (> 50% increase from nadir) was twice as long with atrasentan treatment (505 days vs 254 days; P <.01). The delay in time to PSA progression did not reach statistical significance. Atrasentan generally was tolerated well, and the most common adverse events associated with treatment were headache, rhinitis, and peripheral edema, reflecting the vasodilatory and fluid-retention properties of endothelin-A receptor antagonism. CONCLUSIONS. Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- time to disease progression
- prostate cancer
- hormone-refractory
- atrasentan
- endothelin-A receptor antagonist
- bone metastasis
Publication and Content Type
- art (subject category)
- ref (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Carducci, Michae ...
- Saad, Fred
- Abrahamsson, Per ...
- Dearnaley, David ...
- Schulman, Claude ...
- North, Scott A.
- show more...
- Sleep, Darryl J.
- Isaacson, Jeffre ...
- Nelson, Joel B.
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Cancer
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
